Automated genome engineering platform
Kytopen unveiled Flowfect Discover, an automated high-throughput genome engineering platform.
Source: LinkedIn company description · Retrieved October 13, 2026
Kytopen develops and commercializes genome engineering platforms for gene-modified cell therapy discovery, development, and manufacture.
The Flowfect platform combines microfluidics and automation to deliver genome engineering materials to cells of therapeutic interest.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Kytopen unveiled Flowfect Discover, an automated high-throughput genome engineering platform.
Source: LinkedIn company description · Retrieved October 13, 2026
Flowfect Tx can be combined with Flowfect Discover in process development workflows.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 11, 2026, September 14, 2026, September 18, 2026, September 19, 2026, September 26, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.